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Neurons in the adultmammalian CNS decrease in intrinsic axon growth capacity during development in concert with changes in Kru¨ppel-like
transcription factors (KLFs). KLFs regulate axon growth in CNS neurons including retinal ganglion cells (RGCs). Here, we found that knock-
down of KLF9, an axon growth suppressor that is normally upregulated 250-fold in RGC development, promotes long-distance optic nerve
regeneration in adult rats of both sexes.We identified a novel binding partner, MAPK10/JNK3 kinase, and found that JNK3 (c-Jun N-terminal
kinase 3) is critical for KLF9’s axon-growth-suppressive activity. Interfering with a JNK3-binding domain or mutating two newly discovered
serine phosphorylation acceptor sites, Ser106 and Ser110, effectively abolishedKLF9’s neurite growth suppression in vitro andpromoted axon
regeneration invivo.Thesefindingsdemonstrateanovel,physiologicrolefortheinteractionofKLF9andJNK3inregenerativefailureintheoptic
nerve and suggest new therapeutic strategies to promote axon regeneration in the adult CNS.
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Introduction
Failure of adult CNS neurons to regenerate their axons after in-
jury arises from both intrinsic and extrinsic regulation (Yiu and
He 2006; Moore et al., 2009). For example, inhibitory environ-
mental cues such as glial-derived factors (Yiu and He 2006) and
cell-autonomous signaling pathways such as cAMP, Rho, Rho-
associated kinase, and phosphatase and tensin homolog (PTEN)
(Nicholls and Saunders, 1996; Blackmore and Letourneau, 2006;
Park et al., 2008; Moore et al., 2009; Blackmore et al., 2012) all
play a role in regenerative failure.
We found previously that a family of zinc-finger transcription
factors, the Kru¨ppel-like factor (KLF) family, regulates intrinsic
axon growth in RGCs (Moore et al., 2009). The KLF family of
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Significance Statement
Injured CNS nerves fail to regenerate spontaneously. Promoting intrinsic axon growth capacity has been amajor challenge in the
field. Here, we demonstrate that knocking down Kru¨ppel-like transcription factor 9 (KLF9) via shRNA promotes long-distance
axon regeneration after optic nerve injury and uncover a novel and important KLF9–JNK3 interaction that contributes to axon
growth suppression in vitro and regenerative failure in vivo. These studies suggest potential therapeutic approaches to promote
axon regeneration in injury and other degenerative diseases in the adult CNS.
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transcription factors includes two neurite-growth-enhancing
KLFs (KLF6 and KLF7) and nine neurite-growth-suppressive
KLFs (KLF1, KLF2, KLF4, KLF5, KLF9, KLF13, KLF14, KLF15,
and KLF16) (Moore et al., 2009, 2011; Blackmore et al., 2010).
Expressing KLF7 or knocking out KLF4 in adult CNS neurons
promotes axon regeneration after injury in vivo (Blackmore et al.,
2012; Qin et al., 2013). KLF9, which was shown previously to
suppress neurite growth in embryonic and postnatal RGCs and
young postnatal cortical neurons in vitro, is another strong can-
didate for in vivo regulation of axon regeneration because its
expression increases 250-fold in concert with the developmental
loss of axon growth ability in RGCs (Moore et al., 2009). Func-
tions ranging from improving survival to increasing neurite
growth, branching, and elongation have been observed with
KLF9 expression in some neuronal subtypes (Denver et al., 1999;
Cayrou et al., 2002; Bonett et al., 2009; Lebrun et al., 2013).
Little is known about whether KLF9’s ability to suppress axon
growth is itself regulated by binding partners or posttranscrip-
tional modification. Although KLFs are known to interact with
binding partners such as the scaffold protein mSin3A to regulate
their effects on transcription outside of the nervous system
(Moore et al., 2011), regulatory binding partners have not yet
been described in neurons. To address these issues, we designed
shRNA knock-down constructs targeted against KLF9 and pack-
aged them into adeno-associated viral serotype 2 (AAV2), de-
scribed by us and others to transduce RGCs specifically when
injected intravitreally (Shevtsova et al., 2005; Hellstro¨m et al.,
2009). Here, we show that knocking down KLF9 promotes long-
distance axon regeneration and now identify a novel binding
partner, MAPK10/JNK3 kinase, and two novel phosphorylation
sites, S106 and S110, both required for KLF9’s ability to suppress
neurite growth in vitro and regeneration in vivo. We propose a
model in which JNK3 mediates the activation level of KLF9
through S106/S110 to suppress intrinsic regenerative capacity in
CNS neurons.
Materials andMethods
Animals. All use of animals conformed to the Association for Research in
Vision andOphthalmology Statement for theUse of Animals in Research
and all animal procedures were approved by the Institutional Animal
Care and Use Committee and the Institutional Biosafety Committee of
the University of Miami and the University of California–San Diego.
Sprague Dawley rats and mice of varying ages and either sex were ob-
tained from Harlan Laboratories.
Animal surgery. All surgeries were performed under adequate anesthe-
sia with an intraparietal injection of ketamine hydrochloride, 60 mg/kg,
and xylazine hydrochloride, 8 mg/kg, according to body weight. After
surgery, animals were allowed to recover on a heating pad andwere given
subcutaneous injections of buprenorphine hydrochloride, 0.1 mg/kg,
twice a day for 3 consecutive days to minimize discomfort (Zhao et al.,
2011).
Intravitreal injection of viruses and optic nerve crush. To inhibit KLF9
mRNA expression, the left eye of Sprague Dawley rats of both sexes were
injected intravitreally with a 4 l volume of AAV2-anti KLF9 shRNA-
EGFP or AAV2-anti-luciferase shRNA-EGFP at postnatal day 28 (titers
ranged from2.0 to 3.0 1013 genome copies/ml). Some postnatal day 28
(P28) Sprague Dawley rats were received 4 l of AAV2-EGFP, AAV2-
KLF9JBD-EGFP, AAV2-KLF9S106/110A-EGFP, or AAV2-JBD-P-EGFP
intravitreal injection (titers ranged from 5.0 to 8.9 1012 genome cop-
ies/ml). One week after virus injection, RGCs were labeled retrogradely
with Fluorogold (FG; Fluorochrome) to investigate RGC survival, as
described previously (Chiu et al., 2008). In brief, P35 SpragueDawley rats
were anesthetized and the skull was exposed by a midline incision
through the skin and superficial fascia. Bilateral 2-mm-diameter craniot-
omies were placed 0.5 mm posterolateral to the sagittal and transverse
sutures. A small piece of gelfoam (Gelfoam) soaked in 6% FG was then
placed on the surface of the superior colliculus. For the optic nerve sur-
gery, mice or rats of either sex were use. Two weeks after virus injection
(rats) or at time 0 (mice), the left optic nerve was exposed from outer
canthus and crushed for 5 s with aDumont Fine Science Tools #5 forceps
1.5 mm behind the globe. Care was taken to avoid damaging the blood
supply to the retina. All optic nerve crush procedures were performed by
a surgeon blinded to the viral treatment. Intravitreal injection of 4 l
(rat) or 1 l (mice) of cholera toxin subunit B-conjugated Alexa Fluor
594/555 (CTB-594/555, 10 g/l; Invitrogen) was performed 2 d before
animals were killed as an anterograde tracer to visualize axons and nerve
terminals originating from living RGCs. Animals with any significant
postoperative complications (e.g., retinal ischemia, cataract) were ex-
cluded from further analysis. At different timepoints after the optic nerve
injury, animalswere deeply anesthetized and transcardially perfusedwith
4% PFA in PBS. Optic nerves and retinas were dissected and fixed in 4%
PFA for 1 h and subsequently washed in PBS. Optic nerves were incu-
bated in 20% sucrose at 4°C overnight before mounting in optimal cut-
ting temperature mounting medium before sectioning. Longitudinal
sections (10 m) were made of the entire optic nerve and imaged with a
20magnification objective as above. Photographs were taken, starting
with the furthest regenerating axons and working backward toward the
crush site. Lines were drawn perpendicular to the long axis of the optic
nerve 1, 2, and 5mmpast the crush site. CTB-positive axons passing these
lines were counted in every fourth section per optic nerve in a masked
fashion. The width of the nerve at each line was measured and used to
calculate the number of axons permillimeter of nerve width. The average
number across all sections was combined as axons per millimeter width
to control for volume. The total number of axons extending to distance
(d) in a nerve with a radius of (r) was estimated by summing over all
sections having a thickness t (10 m)as follows: ad  r 2  (average
axons/mm)/t, as described previously (Park et al., 2008).
In vivoKLF9 and luciferase shRNA delivery. To suppress KLF9 expression
in vivo, an inducible RNA polymerase II promoter (Chung et al., 2006) was
subclonedupstreamof four target shRNAsagainst bothmouse and ratKLF9
gene (GeneBank accession numbersNM_010638 andNM_057211, respec-
tively)using target sequences as follows: 5-GGAGGCGCTGCCGGTTAC
GTA-3, 5-TGG CTG CCC AGT GTC TGG TTT-3, 5-CGG GGG ACA
CCT GGA AGG ATT-3 and 5-GCA AAT AAA TGC TTT TGG TAC-3.
These four shRNA sequences in a SIBR cassette (Chung et al., 2006) were
concatenated into a single vector and inserted into pAAV2 vector backbone,
which also expresses GFP as a transduction marker. Luciferase used the
following SIBR cassette: TGGAGGCTTGCTGAAGGCTGTATGCTG-
TTTATGAGGATCTCTCTGATTTTTTTGGCCTCTGACTGAAAATCA-
AGAGTCCTCATAAACAGGACACAAGGCCTGTTACTAGCACTCAC-
ATGGAACAAATGGCCACCGTGGGAGGATGACAA. Both vectors were
kind gifts fromVance P Lemmon, University ofMiami. All constructs were
verified by sequencing.
Immunohistochemistry. For cultured neurons, cultures were fixed us-
ing prewarmed, 37°C 4% paraformaldehyde (PFA). For sections, frozen
15 m sections were fixed with 4% PFA. For retinal flat mount, animals
were killed by transcardial perfusion with 4% PFA and retinas were then
postfixed with 4% PFA for 1 h at room temperature. After rinses in PBS,
samples were blocked and permeabilized in 20% normal goat serum or
20% normal donkey serum with 0.02% Triton X-100 in antibody buffer
containing 150mMNaCl, 50mMTris base, 1%BSA, 100mM L-lysine, and
0.04% Na azide, pH 7.4, for 1 h to reduce nonspecific binding. Samples
were incubated overnight at 4°C in antibody buffer containing primary
antibodies, washed with PBS, incubated in antibody buffer containing
secondary antibodies andDAPI for 1 h at room temperature, andwashed
with PBS. Cultures were left in PBS for imaging and imaged for neurite
growth.
Primary antibodies used for these experiments includedanti- III tubulin
antibody from E7 hybridoma (1:500; Developmental Studies Hybridoma
Bank), anti-FLAG (1:250; Sigma-Aldrich, F7425), anti-GFP (1:200; Aves
Laboratories,GFP-1020), anti-Brn3a(1:100;Millipore,MAB1585)andanti-
RBPMS (1:300; PhosphoSolutions, 1830-RBPMS). Secondary antibodies
were Alexa Fluor 488-, 594-, or 647-conjugated, highly cross-adsorbed anti-
bodies (1:500; Invitrogen).
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RGC survival and viral efficiency analysis. For RGC survival and viral
efficacy analysis after optic nerve crush, the following techniques were
used: briefly, the retinaswere divided into 4 quadrants and each quadrant
was subdivided into 3 areas (central,middle, and peripheral), whichwere
1, 2, and 3 mm from the optic nerve head, respectively. One digital
micrograph was taken randomly from each of the 12 fields. Therefore, 12
images were quantified per retina. Three to four retinas were used for
each condition. FG-positive, Brn3a-positive, RBPMS-positive, or GFP-
positive cells were counted manually in a masked fashion and presented
as cells per millimeter squared in each region of the retina. Whole retinal
RGC density was estimated using the following formula: (DC 3DM
5DP)/9, where DC, DM, and DP represent densities of the central, mid-
dle, and peripheral regions, respectively (Wang et al., 2013).
Quantification of neurite length and neurite number. For high-content
screening of neuronal morphology, including average neurite length,
maximum neurite length, neurite number, and neurite branching, auto-
mated microscopy (ArrayScan VTI or KSR; Cellomics) and image anal-
ysis software (Cellomics Neuronal Profiling BioApplication; Thermo
Fisher Scientific) were used to image and trace neurons using a 5 or
10 objective after immunostaining. RGCs were traced using  III tu-
bulin immunoreactivity to visualize neurites. Neurons with dim signal in
neurites were excluded from analysis due to frequent tracing errors of
faint processes; the threshold for exclusion was established using a pop-
ulation of negative control, no primary antibody-immunostained RGCs.
We previously validated this approach’s consistency and reliability rela-
tive to manually tracing (Moore et al., 2009; Blackmore et al., 2012).
Images and tracing were spot checked to verify that the algorithms were
correctly identifying neurites and quantifying growth. In Figure 4, bars
represent average total neurite length of transfected/transduced neurons.
Cortical slice culture. Cortical slice cultures were prepared as described
previously (Blackmore et al., 2012). Briefly, P5 Sprague Dawley rats were
anesthetized with ketamine on ice and killed in accordance with guide-
lines set by Institutional Animal Care and Use Committees. Brains were
placed in dissection medium containing 37.7 ml of Hank’s balanced salt
solution (HBSS; Invitrogen), 0.8ml of 1 MHEPES (Invitrogen), 1.1ml of
1.2 M D-glucose (Sigma-Aldrich), and 0.4 ml of 1 M magnesium sulfate
(Sigma-Aldrich). Meninges were removed and 350 m coronal sections
of cortex were prepared using a McIlwain tissue chopper. Sections were
trimmed to prepare2 2mmsections of right and left cortex linked by
an intact corpus callosum. Slices were cultured on 30 mm organotypic
polytetrafluoroethylene 0.4 m culture inserts (Millipore; PIC-MORG50) on
35 10mm culture dishes (Falcon) with a culturemedium consisting of
50% basal Eaglemedium (Invitrogen), 18%HBSS (Invitrogen), 2% SM1
50 supplement (STEMCELL Technologies), 4 mM L-glutamine (Invit-
rogen), 6 mg/ml 1.2 M D-glucose (Sigma-Aldrich), and antibiotic/anti-
mycotic (Invitrogen). Two hours later, a 0.5 l drop of viral particles of
each shRNAviruswas applied to each hemisphere. After 2 h of treatment,
sections were rinsed with culture medium to wash out virus. Sections
were rinsed again the next day with culture medium. Forty-eight hours
after transduction, RNAwas collected and quantitative reverse transcrip-
tase PCR (qRT-PCR) was performed using primers and methods de-
scribed previously (Eaton et al., 2008; Jiang et al., 2012).
Purification, culture, transfection, and transduction of primary RGCs
and hippocampal neurons. RGCs were purified by immunopanning as
described previously (Barres et al., 1988;Meyer-Franke et al., 1995;Gold-
berg, Espinosa et al., 2002; Hu et al., 2010; Trakhtenberg et al., 2014).
RGCswere plated onto PDL- and laminin-coated 24-well or 6-well tissue
culture plates in growthmedium as described previously (Meyer-Franke
et al., 1995) and including a homemade supplement similar to B27 (Chen
et al., 2008), forskolin (5 mM), BDNF (50 ng/ml), and CNTF (10 ng/ml).
RGCs were cultured in 10% CO2 for 48 h to analyze neurite growth.
For cotransfection electroporation experiments, after purification,
500,000 RGCs/condition were resuspended in electroporation solution
containing 3.0 g of total DNA in 1:1 ratio (1.5 g gene-1 plus 1.5 g of
gene-2). Concentrations of DNA were adjusted to allow all 3 g to oc-
cupy 2 l of volume, which was then added to 27 l of electroporation
solution for resuspension of cells. Resuspended cells were placed in a
small cell number cuvette (Sigma-Aldrich) and electroporated using
Amaxa program SCN#1. Immediately after electroporation, growth me-
dium was added and the whole solution was placed into a 1.5 ml Eppen-
dorf tube. RGCs were centrifuged for 16 min at 1800 rpm (300 g) in
a standard 8.4 cm rotor Eppendorf tabletop centrifuge before media
resuspension and plating. RGCs were cultured in 10% CO2 for 48 h to
quantify cell neurite growth.
For viral transduction ofRGCs, 10,000P0 or P8RGCs/well were plated
on PDL/laminin-coated 24-well plates. For viral transduction of E18
hippocampal neurons for proteomic analysis [immunoprecipitation
(IP)/Western blots/mass spectrometry (MS)/kinase assays), 1–2.5 mil-
lion hippocampal neurons/well were plated on PDL/laminin-coated
6-well plates. In all cases, 16 h after plating, virus was diluted 1:250 for
lentiviruses and 1:1000 for AAV2 viruses in medium and added to cul-
tured cells. Where noted, multiple viruses were first mixed in a 1:1 or
1:1:1 ratio before dilution in medium. Full medium changes were per-
formed 5.5 and 24 h after virus exposure. For neurite outgrowth assays,
RGCs were fixed in paraformaldehyde 2 d after initial addition of lenti-
viruses and 5 d after application of AAV2 viruses. For protein analysis by
IP andWestern blots, cells were lysed 48 h after transduction. The titer of
AAV2 viruses ranged from 2.0 to 3.0 1013 genome copies/ml. All KLF
and JNK3 lentiviruses ranged in titer from 1.5 to 4 107 pg/ml by P24
titration ELISA (PerkinElmer). There are 2000 molecules of p24 per
physical particle of HIV, so p24 values can be correlated to virus titer.
Cloning of KLF constructs for transfection and virus transduction. EGFP-
KLF9 was obtained in AAV expression vector and was subcloned into
pLenti-MP2 by PCR using Xho1/Xba1 restriction sites 5- and 3- to
EGFP-KLF9, respectively. PCR product was then gel purified and double
digested with both enzymes to create the insert. pLenti-MP2 was double
digested, treated with shrimp alkaline phosphatase, gel purified, and
ligated with inserts with T4 DNA ligase. Once inserted into pLenti-
MP2, EGFP-KLF9 was then mutated at S88/106/110/122 using the
QuikChange II XL Site-Directed and QuikChange Lightning MultiSite-
Directed Mutagenesis Kits (Agilent Technologies) for single and multiple
mutations, respectively.
Primers used formutations (italicized) include: KLF9S88A forward: 5CGA-
CAGTCTGGAAGCTCCAGATGAGGATATGGG 3; KLF9S88A reverse: 5
CCCATATCCTCATCTGGAGCTTCCAGACTGTCG 3; KLF9S88E forward:
5GCGACAGTCTGGAAGAGCCAGATGAGGATATGGGATCCG3;
KLF9S88E reverse: 5CGGATCCCATATCCTCATCTGGCTCTTCCAGACT-
GTCGC 3; KLF9S106A forward: 5GAATCTGGGTCGGCCCCTTCCCA-
CAGCCCGGAGGAGAG 3; KLF9S106A reverse: 5CTCTCCTCCGGG-
CTGTGGGAAGGGGCCGACCCAGATTC 3; KLF9S106E forward: 5GAA-
TCTGGGTCGGAGCCTTCCCACAGCCCGGAGGAGAG 3; KLF9S106E re-
verse: 5CTCTCCTCCGGGCTGTGGGAAGGCTCCGACCCAGATTC 3;
KLF9S110A forward: 5GAATCTGGGTCGAGTCCTTCCCACGCCCCG-
GAGGAGAG3; KLF9S110A reverse: 5CTCTCCTCCGGGGCGTGGGAAG-
GACTCGACCCAGATTC 3; KLF9S110E forward: 5GAATCTGGGTC-
GAGTCCTTCCCACGAGCCGGAGGAGAG 3; KLF9S110E reverse: 5
CTCTCCTCCGGCTCGTGGGAAGGACTCGACCCAGATTC3;KLF9S122A
forward: 5GCAGCGCGCCCGCCCCGCTCTCCC 3; KLF9S122A re-
verse: 5 GGGAGAGCGGGGCGGGCGCGCTGC 3; KLF9S122E for-
ward: 5 CTGGCAGCGCGCCCGAGCCGCTCTCCCTC 3; KLF9S122E
reverse: 5GAGGGAGAGCGGCTCGGGCGCGCTGCCAG 3;
KLF9S106/110A forward: 5GAATCTGGGTCGGCCCCTTCCCACGC-
CCCGGAGGAGAG 3; KLF9S106/110A reverse: 5CTCTCCTCCGGG
GCGTGGGAAGGGGCCGACCCAGATTC 3; KLF9S106/110E forward:
5ACCGAATCTGGGTCGGAGCCTTCCCACGAGCCGGAGGAGAGA
CAG 3; KLF9S106/110E reverse: 5 CTGTCTCTCCTCCGGCTCGTG
GGAAGGCTCCGACCCAGATTCGGT3; KLF9223–233 Forward: 5CC
TCACAAAGCACGCCAAGCGATCGAAAAAGG 3; KLF9223–233
reverse: 5CCTTTTTCGATCGCTTGGCGTGCTTTGTGAGG 3;
KLF9SID(1–21)Forward:5GTCGAAAGAATTCGGTACCAAGTCGA
AAGAATTCGGTA3; andKLF9SID(1–21) reverse: 5TACCGAATTCTT
TCGACTTGGTACCGAATTCTTTCGAC 3.
Flag-tagged mCherry and flag-tagged JNK31 were kind gifts from
V.P. Lemmon (University of Miami). JNK31 was subcloned into the
SpeI/XbaI site in pLenti-MP2 expression vector with flag-mCherry
upstream before packaging into lentivirus. Flag-mCherry and flag-
mCherry-JNK31 lentiviruses were used between 1.5 and 4.0  107
pg/ml assayed as above.
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Protein extraction, MS analysis, IP, Western blot, and in vitro kinase
assays. For MS analysis, we used purified P0 rat RGCs transduced with
lentivirus to express flag-tagged KLF9. KLF9 is expressed at this age,
although its expression continues to rise postnatally. Although it would
be ideal to perform IP for endogenous KLF9 from older RGCs when its
expression is high for MS, cell and protein yields from older animals are
significantly reduced. For example, from150 P0 animals, we could purify
10million RGCs, which in turn yielded200g of protein, which is still
at the lowest recommended range for IP/MS experiments for most mass
spectrometers. Therefore, we used purified P0 rat RGCs transduced with
KLF9 for initial IP/MS, followed by validating hits with older RGCs.
RGCs were purified by immunopanning and transduced with virus as
above. Forty-eight hours after lentiviral exposure with Flag-KLF9, RGC
proteins were extracted with a custom lysis buffer containing 125 mM
Tris-HCl, 100 mMNaCl, 0.1% Genapol C-100 (EMD Biosciences), 0.1%
trehalose, 0.1% n-octyl-b-D-glucopyranoside (EMD Biosciences), and
protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific).
Flag-tagged protein was then immunoprecipitated using anti-Flag affin-
ity M2 gel (Sigma-Aldrich, A2220), and resolved on a 4–10% gradient
Phastgel (GE Healthcare). A strip of bands were excised and sent for MS
analysis at the Scripps Research Institute. Sample was analyzed using an
LC MS/MS LTQ Orbitrap mass spectrometer. MS data were searched
with MASCOT and SEQUEST and peptide spectra were checked manu-
ally and blasted with SWISSPROT databases.
For hippocampal neuron IP andWestern blots, hippocampal neurons
were dissected anddissociated as described previously (Bradke andDotti,
1997). Eight to 10million cells were used per condition. Cells were virally
transduced and cultured as described above. At 48 h, cells were lysed first
with cytosolic extraction buffer (10 mM PIPES, 100 mM NaCl, 300 mM
sucrose, 3 mM MgCl2, and protease/phosphatase inhibitor cocktails;
Thermo Fisher Scientific). Supernatant was removed and nuclear mate-
rial resuspended with 50–100 l of custom lysis buffer (see above). Sus-
pension was rotated for 5 min at 4°C. Nuclear suspension was then
centrifuged at 600 RPM (34  g) for 5 min at 4°C. Supernatant was
collected and used for IP and Western blots.
For retina IP andWestern blots, retinaswere collected from80–90P10
rats and dissociated with papain as described previously (Barres et al.,
1988;Meyer-Franke et al., 1995;Goldberg, Espinosa et al., 2002;Hu et al.,
2010; Yu et al., 2014); cell suspensions were lysed immediately and nuclei
fractionated directly in the same way as hippocampal neurons described
above. Supernatant was collected and used for IP and Western blots.
IP was performed with protein G dynabeads (Invitrogen), BS3
cross0linking reagent (Thermo Fisher Scientific) and antibodies. Anti-
bodies used included anti-FLAG (15g/condition for IP; 1:200 forWest-
ern blot; Sigma-Aldrich, F7425 or F3165), anti-GFP (15g/condition for
IP; 1:200 for Western blot; Invitrogen, A11122). Cell extracts were sepa-
rated by SDS-PAGE on 4–20% Tris-Glycine gels (Invitrogen) and elec-
trotransferred to PVDFmembranes (Millipore) at 25 V for 2 h using the
XCell SureLock Mini-Cell (Invitrogen). Membranes were blocked with
Blok-CH chemiluminescent blocker (Millipore) and the antibody reac-
tion performed with the SNAP I.D. system (Millipore). Other primary
antibodies used for these experiments included anti-KLF9 antibody (1:
200; Santa Cruz Biotechnology, SC12994) and anti-JNK3 (1:200, Milli-
pore, 05–893). Secondary antibodies were HRP-conjugated anti-mouse,
anti-rabbit, and anti-goat IgGs (1:400; Santa Cruz Biotechnology Bio-
technology or Rockland, TRUBLOT). Immunopositive bands were visu-
alized by chemiluminescence with ECL (Thermo Fisher Scientific) and
imaged on a LAS-3000 (Fujifilm). Densitometry was performed with
Multi Gauge version 3.1 software (Fujifilm).
For in vitro kinase assays, E18 hippocampal neurons were transduced
with flag-tagged wild-type KLF9, KLF9JBD, or KLF9S85/88/95/106/110A
mutants. One hundred million cells were used per condition. Cells were
lysed and nuclei were fractionated and immunoprecipitated with mag-
netic Dynabeads (Life Technologies, 10007D) conjugated with anti-flag
antibody. Eluents were combined with recombinant JNK3 (Millipore,
14–501) and radiolabeled [	- 32] ATP for a standard in vitro kinase assay.
Briefly, 2.5l of 10 reaction buffer was added each tube. Next, 2.5l of
ATF-2-positive control or 2.5 l of 10 buffer for negative control was
added to corresponding tubes. Then, 2.5 l (13–69 ng) of active JNK3/
SAPK1bwas added to each sample tube and control, followed by 7.5l of
dH2O and then 10l of diluted [-
32P] ATPmixture to each tube. Tubes
were then incubated for 10 min at 30°C and the reaction stopped by
addition of 5l/tube of 3%phosphoric acid.Mixtureswere then resolved
on 4–20% Tris-glycine gradient SDS-PAGE gel (Invitrogen), vacuum
dried, and the film developed for 3 d.
Experimental design and statistical analysis. For all in vivo experiments,
at least three animals (rats for shRNA KLF9 and mice for JNK3
/

experiments) of either sex were used per condition. Two-tailed Student’s
t test or one-way ANOVA was used for statistical analysis of distance
traveled by regenerating axons and RGC survival. p 0.05 was regarded
as statistically significant using GraphPad Prism software. For in vitro
neurite tracing, data analysis was performed using the JMP version 8
statistical package program (SAS Institute). Two-tailed Student’s t test
was used for statistical comparison of two samples. p 0.05was regarded
as statistically significant. For KLF alignments, clustalW2 software was
used on human KLF genes. Genes were grouped and colored by the
presence of known motifs. In the figures, all data are displayed as means
and SEM and significance is represented with asterisks.
Results
Anti-KLF9 shRNA promotes RGC survival and axon
regeneration
Wedesigned four concatenated SIBR shRNAconstructs targeting
both rat and mouse KLF9 mRNA transcripts. Knock-down effi-
ciency was tested in cortical slice cultures and purified P10 RGCs
in vitro by qRT-PCR and Western blot. More than 80% knock-
down of mRNA and 50% knock-down of protein were ob-
served with anti-KLF9 shRNA relative to an anti-luciferase
control virus in both models (Fig. 1A,B). We then investigated
whether KLF9 expression changes in vivo after optic nerve injury.
In an adult rat optic nerve crushmodel, RGC death begins at 3–5
d and peaks at 1–2 weeks after injury (Berkelaar et al., 1994).
Compared with uninjured controls, 3 d after optic nerve injury
RGCs showed no significant change in KLF9 protein expression,
quantified by both Western blot and immunofluorescence (Fig.
1C,D). Therefore, KLF9 expression is high in RGCs but does not
change after optic nerve injury.
BecauseKLF9 overexpression suppresses axon growth in vitro,
we next examined the effects of KLF9 knock-down. Knocking
down KLF9 by shRNA in purified P8 RGCs increased neurite
outgrowth significantly (Fig. 1E), demonstrating that endoge-
nous levels of KLF9 expression limit neurite growth actively in
RGCs. To examine the effects of KLF9 knock-down in vivo, AAV2-
shRNA-anti-KLF9 virus was injected intravitreally 2 weeks before
and retrograde labeling of RGCswas performed 1week before optic
nerve injury. High RGC transduction specificity and efficiency as
measured by colocalization with RGC-specific marker RBPMS
(Kwong et al., 2010; Rodriguez et al., 2014) were observed in both
control virus- and anti-KLF9 virus-injected eyes 2 weeks after intra-
vitreal injection (Fig. 1F). Measurement of FG-positive RGCs 2
weeks after injury showed a significant increase in RGC survival
after anti-KLF9 shRNA treatment relative to control (Fig. 1G,H).
There was also a significant increase in the number of CTB-
positive regenerating axons in the anti-KLF9 experimental group
(Fig. 1 I, J). Regenerating fibers passed 5 mm from the crush site,
reaching the optic chiasm. Most of the fibers entering the optic
chiasm were noted to cross to the contralateral side (Fig. 1 I, I).
Significantly fewer CTB-positive fibers were observed in the
anti-KLF9 group at 1 week after injury (Fig. 1K ) and many
more GFP-positive degenerating fibers were observed than
CTB-positive regenerating fibers, ruling out a sparing effect
and confirming progressive regeneration after 2 weeks. There-
fore, shRNA-mediated knock-down of KLF9 expression in-
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Figure 1. Anti-KLF9 shRNA promotes RGC survival and axon regeneration at 2 weeks after optic nerve injury. A, AAV2-shRNA anti-KLF9 decreased KLF9 expression levels in cortical slice culture
and purified P10 RGCs. B, Western blot for KLF9 in RGCs purified after intravitreal injection of AAV2-KLF9 shRNA or AAV2-anti-luceferase control. C, Immunohistochemistry of KLF9 in retinal slides
in control and at 3 d and 5 d after optic nerve injury. D, Western blot for KLF9 in RGCs purified from P18 rats 3 d after optic nerve injury and uninjured (normal) control. (Figure legend continues.)
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creased RGC survival and promoted axon regeneration after
optic nerve injury in vivo.
KLF9 is bound and phosphorylated by JNK3
We next sought to identify KLF9-binding partners, hypothesiz-
ing that such proteins may contribute to KLF regulation of axon
growth and regeneration. We first investigated whether mSin3A
binds KLF9 in neurons in a manner similar to what was reported
previously for non-neuronal cells (Moore et al., 2011), by immu-
noprecipitating KLF9 protein from whole retinal lysate and
Western blotting for mSin3A. mSin3A was present in both input
and unbound flow-through, but not in immunoprecipitated el-
uent (Fig. 2A), indicating that, although mSin3A is expressed in
the retina, it does not bind KLF9. To probe for novel binding
partners, we performed IP/MS on whole retinal lysates and puri-
fied P0 rat RGCs transducedwith lentivirus to express flag-tagged
KLF9. We did not identify mSin3a or any other cofactors that
could regulate KLF9 function. However, MAPK10/JNK3 (Fig.
2B, box) was identified with six independent peptides detected
from eight unique and 19 total spectra demonstrating 13% pro-
tein coverage. Multiple peptides unique to JNK3 protein sug-
gested unequivocal identification (Fig. 2C). JNK3 expression
increases during RGC development (Fig. 2D) and parallels the
developmental increase in KLF9 expression (Moore et al., 2009),
suggesting a possible connection between KLF9 and JNK3 and
the RGCs’ developmental decrease in intrinsic axon growth abil-
ity (Goldberg, Klassen et al., 2002).
The binding interaction between KLF9 and JNK3 was further
verified by co-IP of endogenous KLF9 and Western blot for en-
dogenous JNK3 in P10 rat RGCs (Fig. 2E). Without a commer-
cially available JNK3 IP antibody, we were not able to perform a
reverse IP of endogenous JNK3 to further confirm the binding
interaction. To explore subcellular colocalization, we transfected
tagged proteins in purified RGCs and immunostained for each.
JNK3’s nuclear localization has been well described (Song et al.,
2007; Turjanski et al., 2007; Abdelli et al., 2009; Pan et al., 2009)
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(Figure legend continued.) E, KLF9 knockdown increased neurite growth in purified P8 RGCs.
RGCs were treated with AAV2-shRNA anti-KLF9-GFP or AAV2-shRNA anti-Luciferase-GFP and
cultured in growth media for 5 d. Neurites were labeled by -III-tubulin staining (red).
F, Images of the retinal segments showing GFP-positive virus transduced cells were co-labelled
with RGC-specific marker RBPMS. G, Images of the retinal segments showing FG labeled RGCs.
H, RGC quantification demonstrated significantly higher RGC density in anti-KLF9 group than
the injury control group. **p  0.01, one-way analysis of variance; N  3–4 per group.
I, Images of the optic nerve sections showing CTB-labelled regenerating axons at 2 weeks after
optic nerve injury. Asterisks, lesion sites. High-magnification images of the boxed area in (I)
showed fibers extending contralaterally through the optic chiasm of an anti-KLF9 virus-treated
animal (I). J, Significantly more fibers regenerated after KLF9 knockdown compared to con-
trol group. **p 0.01, Student t-test; N 3–4 per group. I,I, High-magnification images
of the boxed area in I. K, Images of the optic nerve sections showing CTB-labelled regenerating
axons at 3 d and 1week after optic nerve injury for AAV2-shRNA anti-KLF9-GFP or AAV2-shRNA
anti-Luciferase-GFP. Asterisks, lesion sites. Error bars, SEM. Scale bars, 200m.
Figure 2. KLF9 is bound by JNK3 in neurons. A, mSin3a is present in the retina but does not bind KLF9. Retina lysate from P10 rats was immunoprecipitated for KLF9 and Western blotted for
mSin3a or KLF9. B, Purified P0 rat RGCs virally transduced with flag-tagged KLF9 were lysed and immunoprecipitated for flag. The IP lane (box) was sent for MS analysis. C, JNK3 is identified from
KLF9 IP/MS.MAPK10/JNK3was detectedwith six independent peptides (identified fromeight unique and 19 total spectrawith95%confidence, yellow) andwith 13%coverage (oxidized residue
in green). D, JNK3 mRNA expression (arbitrary units) in developing RGCs from a previously described microarray dataset (Wang et al., 2007) shows robust upregulation during development.
E, Endogenous KLF9 co-IPs with JNK3. Retinas from P10 rats were immunoprecipitated for KLF9 andWestern blotting for anti-KLF9, anti-JNK3, and anti--actin antibodies, as marked. F, Confocal
nanoscopy imagingof GFP-KLF9- and Flag-JNK3-electroporatedRGCs demonstratednuclear colocalization. Asterisk indicates that not all cellswere successfully cotransfected. Fluorescence intensity
of KLF9, JNK3, and TOPRO-3were calculated separately and compared along the line in the cell cotransfectedwith both proteins (F, arrows). Intensities showed higher similarity between KLF9 and
JNK3 thanTOPRO-3 (red lines). F, High-magnification images of the boxed area in F. Scale bar, 10m. I, input; E, eluent; F, flow-through.
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Figure 3. Identification of JNK3-binding domain and potential serine/threonine phosphorylation sites of KLF9. A, KLF9 structural analysis revealing potential JNK3-binding domains. ClustalW2
alignment shows region spanning R223 to I233 near C terminus of KLF9, as well as similar regions on subfamily relatives KLF13, KLF14, and KLF16, as well as KLF10 and KLF11, closely conforming
to the known consensus JNK3 “DEJL” docking domain. B, MIT Scansite surface analysis of KLF9 full-length protein reveals potential phospho-acceptor sites at S88, S95, S106, and S110. C, MIT
Scansite-predicted surface accessibility of KLF9protein (1 indicates exposed residues;1 indicates buried or inaccessible residues).D, Schematic of a subset ofmutant constructs for KLF9. ZF, Zinc
finger domains. E, F, R223–I233 of KLF9 is necessary for KLF9–JNK3 interaction in neurons. E18 hippocampal neuronswere cotransducedwith Flag-mCherry-JNK3 and GFP, GFP-KLF9, or GFP-KLF9
R223-I233 deletion mutant (GFP-KLF9 223–233) constructs using lentivirus. Cells were immunoprecipitated for GFP andWestern blotted for flag (E) or GFP (F). G, H, JBD-P of KLF9 is sufficient for
KLF9/JNK3 interaction in neurons. E18 hippocampal neurons were virally cotransduced with Flag-mCherry-JNK3 and either CP or JBD-P constructs (Figure legend continues.)
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and, consistent with previous research, JNK3 was primarily de-
tected in the nucleus of RGCs (Fig. 2F). Coloc2 analysis showed
colocalization (p  1.00) and ImageJ plot analysis showed a
higher degree of similarity betweenKLF9 and JNK3 than between
KLF9 and a control nuclear protein, TOPRO-3 (Fig. 2F,F), not
only suggesting nuclear specificity, but also supporting colocal-
ization at the limits of confocal light microscopy. Together, these
data demonstrate that JNK3 is a novel binding partner of KLF9 in
RGCs.
Where does JNK3 bind KLF9 and does this interaction lead to
KLF9 phosphorylation? Because there is no complete x-ray crys-
tal structure for KLF9, we performed a surface modeling analysis
using Scansite (scansite.mit.edu). Analysis revealed a surface
consensus JNK family docking domain sequence, arginine 223 to
isoleucine 233 (R223-I233), near KLF9’s C terminus (Fig. 3A),
and four potential serine/threonine kinase phosphorylation sites
on KLF9, S88, S95, S106, and S110 (Fig. 3B), all with predicted
high surface accessibility (Fig. 3C). Although potential phospho-
acceptor sites for MAPK family kinases appear throughout the
KLF family, only KLF9, KLF13, KLF14, and KLF16 (BTEB sub-
family of KLFs) and KLF10 and KLF11 have sequences closely
conforming to the JNK consensus docking site (Fig. 3A). We
assessed the biochemical relevance of these residues by transduc-
ing E18 hippocampal neurons (used for their similar neurite
growth-inhibited response to KLF9 expression (Moore et al.,
2009) and their greater cell and protein yields) with a wild-type
KLF9, KLF9SID deletion mutant lacking the mSin3a-binding
site, a KLF9223–233 deletion mutant lacking the JNK3 consensus
binding site, or a KLF9S88/95/106/110A mutant substituting the pu-
tative phospho-acceptor sites with nonphosphorylatable alanines
(Fig. 3D).Whenhippocampal neuronswere transducedwith len-
tiviral GFP, GFP-KLF9, or GFP-KLF9223–233 along with flag-
mCherry-JNK3 after nuclear fractionation and co-IP, only in the
GFP-KLF9 elution did we detect flag-mCherry-JNK3 (Fig.
3E,F). Conversely, the putative JNK3-binding domain of KLF9
(R223-I233) peptide (JBD-P) fused with GFP and a nuclear
localization sequence (NLS), but not the NLS control peptide
construct (CP) (Fig. 3G), immunoprecipitated JNK3 from hip-
pocampal nuclear extracts (Fig. 3H). Furthermore, JBD-P but
not CP was able to decrease the interaction between KLF9 and
JNK3 (Fig. 3H, I). Therefore, the R223–I233 domain of KLF9 is
necessary and sufficient for JNK3 binding and acts as an inhibitor
of the KLF9–JNK3 interaction. When recombinant JNK3 was
added to immunoprecipitated KLF9 protein, only wild-type
KLF9, but not either of the mutants, incorporated radiolabeled
[	-32] ATP (Fig. 3J). Therefore, recombinant JNK3 is capable of
phosphorylatingKLF9protein and this phosphorylation depends
on the JNK-binding domain (R223-I233) and the presence of one
or more identified serine residues (S88/S95/S106/S110).
JNK3-binding domain and S106 and S110 are critical to
KLF9’s function in suppressing axon growth
We next investigated whether the KLF9–JNK3 interaction regu-
lates KLF9’s ability to suppress neurite growth in RGCs. When
KLF9–JNK3 binding was disrupted either by deleting the JNK3-
binding domain (KLF9JBD) or by delivering the JBD-P, KLF9’s
suppression of RGC neurite growth was abolished (Fig. 4A,B).
Although the N-terminal mSin3A-interacting domain (SID) has
been shown to be critical for KLF9’s function in non-neuronal
cells (Grzenda et al., 2009), its deletion did not affect KLF9’s
suppressive effect on neurite growth in RGCs (Fig. 4A,B). Fur-
thermore, coexpressing JNK3withKLF9 onP0RGCs potentiated
wild-type KLF9’s neurite growth-suppressive activity, although
JNK3 expression did not affect neurite growth on its own (Fig.
4C). The kinase activity of JNK3 is essential for this functional
interaction because a kinase-dead JNK3mutant (Ho et al., 2006)
had no ability to potentiate KLF9’s neurite growth suppression
(Fig. 4C). Therefore, KLF9 and JNK3 interact functionally to
suppress neurite growth in RGCs.
To address which of the four potential serine phosphorylation
acceptor sites are crucial forKLF9’s function in neurons, different
serine-to-alanine nonphosphorylatable and serine-to-glutamate
phosphomimic mutants of KLF9 were transduced into RGCs by
lentivirus at P0 and P8, examining both ages to assess function in
the context of lower (P0) or higher (P8) levels of endogenous
KLF9 (Moore et al., 2009). In all cases, the KLF9 constructs were
found to localize to RGC nuclei after transduction (Fig. 4A),
suggesting that none of the mutations affected nuclear localiza-
tion. Of all of the phosphomutants tested, only S106/S110 proved
functionally relevant in neurite growth assays. When both resi-
dues were mutated to phospho-null alanines (S106/110A),
KLF9’s ability to suppress neurite growth was abolished in both
P0 and P8 RGCs (P0, Fig. 4A,B; P8, data not shown). Conversely,
when both were mutated to phosphomimic glutamates (S106/
110E), KLF9’s suppression of neurite growth was potentiated at
both ages (P0, Fig. 4A,B; P8, data not shown). Furthermore,
phosphomimic substitutions were able to rescue the JNK3-binding
domain deletion: RGCs transducedwith KLF9JBD/S106E/S110E dem-
onstrated a suppressed neurite growth capacity similar to the
full-length S106/110E mutant (Fig. 4A,E), demonstrating that
phosphorylation of these two serines can rescue KLF9’s neurite
growth suppression in the absence of JNK3 binding. Therefore,
the phosphorylation state of S106/S110 modulates KLF9’s sup-
pressive effect on neurite growth, suggesting a novel mode of
KLF9 regulation, consistent with the JNK3 binding and phos-
phorylation shown above.
Disrupting KLF9–JNK3 interaction or expressing KLF9
S106A/S110Amutants enhance optic nerve axon regeneration
We first examined JNK phosphorylation after optic nerve injury,
which was described previously to increase phosphorylated JNK
(Fernandes et al., 2012). In the absence of pJNK3-specific anti-
bodies, we used JNK knock-out mice to determine isoform
contribution to expression after injury. Inwild-typemice, immu-
nofluorescence against pJNK showed a low baseline level that
increased after optic nerve injury (Fig. 5A,B). A similar increase
after optic nerve injury was detected in JNK2-null mice, but not
in JNK2/3 double-nullmice (Fig. 5A,B), indicating that the pJNK
increase seen after optic nerve injury reflects JNK3’s contribution
to phosphorylation.
We next studied whether knocking out JNK3, which likely has
many substrate targets, contributes to RGC survival or axon re-
generation. We found that JNK3 KO promoted RGC survival
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(Figure legend continued.) (G), immunoprecipitated for GFP and Western blotted for flag.
Flag-mCherry-JNK3was only detectedwith the JBD-P construct (G).H, I, JBD-P reduces KLF9–
JNK3 interaction. E18 hippocampal neurons were virally cotransduced with GFP-KLF9, Flag-
mCherry-JNK3, and the CP or JBD-P, immunoprecipitated for KLF9, andWestern blotted for flag
or GFP (I). Densitometry quantification of blot bands showed an average of 38%decrease in the
amount of flag-mCherry-JNK3 pulled down by the JBD-P coexpression group compared with
the CP condition (I). J, KLF9 incorporation of radiolabeled [- 32P] ATP depends on JNK-binding
domain (JBD) and identified serine residues. E18 hippocampal neurons were transduced with
flag-tagged wild-type KLF9, KLF9JBD, or KLF9 S85/88/95/106/110A mutants. Cells were immuno-
precipitated for flag. Eluents were combined with recombinant JNK3 and radiolabeled [	- 32]
ATP in a standard in vitro kinase assay. Incorporation of radioactivity was only observed in the
eluents from wild-type KLF9 transduced neurons. *p 0.05, 2-tailed Student’s t test, n 3.
Error bars indicate SD. I, Input; E, eluent; F, flow-through.
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Figure 4. JNK3-binding domain and serines S106 and S110 are critical to KLF9’s function in suppressing axon growth. A, Images of RGCs immunostained for GFP (transduced cells) and -III
tubulin (red). P0 RGCswere virally transducedwithmCherry, KLF9 ormutants of KLF9with GFP reporter. Scale bar, 50m.B–E, Quantification of neurite growth of RGCs in different conditions. The
KLF9JBD but not the KLF9SID deletion abolishedwild-type KLF9’s growth-suppressive effect on P0 (B) and P8 (data not shown) RGCs. JNK3 potentiated KLF9’s neurite growth-suppressive activity
on P0 RGCs; however, JNK3 alone or a kinase-dead mutant (KD) showed no effect (C). JBD-P but not CP abolished KLF9’s suppressive effect on P0 RGCs cotransduced with KLF9 (D). KLF9 S106/110A
substitutions abolishedwild-type KLF9’s growth-suppressive effect, whereas KLF9 S106/110E enhanced KLF9’s suppressive effect on P0 (A) and P8 (data not shown) RGCs. Phosphomimic S106/S110E
substitutions rescuedKLF9 suppression onP0RGCneurite growth even in the absence of theR223-I233 JNK3-bindingdomain (E). *p0.05, one-wayANOVAwithBonferroni/Dunn correction;n
3–5. Error bars indicate SD., NS, Not significant.
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(Fig. 5C,D), but not axon regeneration, significantly compared
with wild-type animals (Fig. 5E,F), indicating that JNK3 regu-
lates RGC survival and axon regeneration through different
mechanisms and likely has many targets other than KLF9. This is
consistent with recent data on a kinase upstream of JNKs, dual
leucine zipper kinase (DLK) because deletion of DLK promotes
RGC survival but reduces the number of regenerating axons in-
duced by PTEN deletion after optic nerve injury (Watkins et al.,
2013; Welsbie et al., 2013; Welsbie et al., 2017).
We narrowed in on the more specific question of whether
disrupting the KLF9–JNK3 interaction or altering S106/110
phosphorylation enhances RGC survival or axon regeneration
after optic nerve injury in vivo. AAV2 packagedwithGFP, JBD-P,
KLF9S106/110A, or KLF9JBD were injected intravitreally 2 weeks
before optic nerve injury to allow adequate expression in RGCs;
axon regeneration was assessed 2 weeks after optic nerve injury.
The transduction efficiencies of all the constructs were similar
and 80% (data not shown, similar to the AAV2 shRNA anti
KLF9; Fig. 1E).None of the constructs affectedRGC survival after
injury (Fig. 6A,B). An increased number of regenerating axons
were observed up to 1000 m from the site of injury in animals
treated with JBD-P, KLF9S106/110A, or KLF9JBD AAV2 (Fig. 6C,D).
Therefore, disrupting the KLF9–JNK3 interaction by introducing
JBD-P or KLF9JBD or expressing KLF9 with nonphosphorylatable
alanine substitutions at S106 and S110 increases the regenerative
potential of adult RGCs in vivo.
Discussion
Together, these data demonstrate three important, related find-
ings. First, KLF9 expression contributes to the cell-intrinsic sup-
pression of axon regeneration in vivo and knock-down by RNAi
promotes long-distance axon regeneration. Axon regeneration
promoted byKLF9 genomic excision using a floxedKLF9 allele or
CRISPR/Cas9 technology could further validate these results;
however, in contrast to gene deletion, inhibition of KLF9 via
virally delivered shRNA could be a more useful tool for potential
future translational application. Themechanisms forKLF actions
in different neurons and on different cellular phenotypes have
not been well studied, but KLFs may have opposing effects in
different neurons, implying differing mechanisms. For example,
inconsistent with its suppressive effect on RGC survival and axon
growth, KLF9 improved Purkinje cell survival in organotypic
cultures (Lebrun et al., 2013) and increased neurite growth,
branching, and elongation in Neuro-2a and XTC-2 cell lines and
Figure 5. JNK3 knock-out promoted RGC survival but not axon regeneration. A, Immunofluorescence for retinal ganglion cells using -III tubulin (green) and phosphorylated JNK (red) in
wild-type control retinal sections and after optic nerve injury in wild-type mice, Jnk2
/
, and Jnk2 and 3
/
. B, pJNK quantifications for control and optic nerve injury. C, Images of the retina
showing RGC-specific markers RBPMS (green) and Brn3a (yellow) in JNK3 knock-out (KO) and age-matched wild-type (WT) mice before and 2 weeks after optic nerve crush. D, RGC quantification
demonstrated similar RGC density in JNK3 KO andWT control mice before the optic nerve injury. Two weeks after optic nerve injury, however, RGC density in JNK3 KOmice was significantly higher
than in WT animals (*p 0.05, **p 0.001, one-way ANOVA; n 5 per group; NS, Not significant). E, Images of the optic nerve sections showing CTB-labeled axons 2 weeks after optic nerve
injury. Asterisks indicate lesion sites. F, A similar number of regenerating fibers was observed in JNK3 KO andWT control animals. Error bars indicate SE. Scale bar, 200m.
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dissociated cerebral hemisphere cultures (Denver et al., 1999;
Cayrou et al., 2002; Ronald Bonett et al., 2009). We hypothesize
that such differences may be due to differences in primary neu-
rons versus cell lines and in KLF cofactor expression and note the
in vivo validation of our findings. Here, we find a robust effect on
both RGC survival and axon regeneration of KLF9 knock-down
in the adult rat delivered just before optic nerve injury. These data
suggest that although many KLFs are developmentally regulated
at the time RGC axon growth declines early postnatally, decreas-
ing KLF activity acutely in adult rat and mice is sufficient to
promote regeneration and this KLF-mediated decline in axon
growth capacity is reversible.
Interestingly, we showed previously that KLF4 knock-down
during early development promoted axon regeneration but not
survival after optic nerve injury in the adult mice (Moore et al.,
2009), suggesting that KLF4 and KLF9 may regulate neuron sur-
vival and perhaps axon regeneration by different mechanisms.
It is likely that these differences are mediated by the structural
and binding partner differences between the two proteins. For
example, KLF4 was not able to pull down JNK3 from whole
retinal lysates (data not shown). Further studies on the differ-
ences in KLF biology across cells and tissues throughout the
CNS will lead to better understanding of their regulation of
survival and axon regeneration.
Second, these data reveal an important interaction between
KLF9 and a novel KLF9-binding partner, JNK3,which phosphor-
ylates KLF9 in neurons. Activated MAPKs in injured neurons of
both the CNS and PNSmediate changes in the expression and/or
activation levels of transcription factors such as c-Jun, STAT-3,
and ATF2 (Herdegen and Leah, 1998; Tsujino et al., 2000;
Schweizer et al., 2002; Powell et al., 2014)—and now KLFs.
JNK3’s activation after axon injury and role in promoting RGC
death has been well studied (Fernandes et al., 2012), although
some prior work is not consistent with our observation of in-
creased RGC survival in JNK3 knock-out animals after optic
nerve injury (Quigley et al., 2011). Conditionally knocking out
c-jun, one of JNK3’s substrates, was found to improve survival
significantly (Fernandes et al., 2012). Paradoxically, c-jun expres-
sion has also been shown to be an important regulator of success-
ful regeneration after injury (Raivich andMakwana, 2007; Ruff et
Figure6. Disrupting the KLF9–JNK3 interaction or expressing KLF9 S106/110Amutants enhance optic nerve axon regeneration 2weeks after optic nerve injury.A, Images of Brn3a-positive cells
in retinal segments fromdifferent groups. Scale bar, 100m.B, Quantification of RGC survival showedno significant differences amongall groups.C, Images ofmergedoptic nerve sections showing
CTB-labeled regenerating axons. Scale bar, 200m. Asterisks indicate lesion sites. D, Significantly more regenerating fibers were observed in JBD-P, KLF9 S106/110A, and KLF9JBD treated animals
than in control animals. *p 0.05, **p 0.01, one-way ANOVA; n 4. Error bars indicate SEM.
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al., 2012). This dual functionality has also been observed at the
kinase level with DLK, a kinase upstream of JNKs, which was
shown to have both proregenerative and proapoptotic effects on
RGCs after optic nerve injury (Watkins et al., 2013;Welsbie et al.,
2013). JNK3’s direct role in axon regeneration, however, has not
been well characterized previously. Some previous research on
cultured neurons showed that lack of JNK3 delayed neurogenesis
(Barnat et al., 2010) and impaired regenerative neurite outgrowth
(Tonges et al., 2011). In the current study, we showed that JNK3
played a role in regulating intrinsic regenerative capacity in neu-
rons. It interacts with KLF9 to suppress neurite growth in RGCs
and the disruption of their interaction promotes axon regenera-
tion after optic nerve injury in vivo. Interestingly, globally knock-
ing out JNK3 throughout development does not promote axon
regeneration after optic nerve injury. JNK2, which is highly struc-
turally and functionally related to JNK3 (Fernandes et al., 2012),
could compensate for JNK3’s loss during development. Acute
knock-downof JNK3 in adult animalswould be useful to confirm
the role of JNK3 on axon regeneration and overexpression of
exogenousKLF9 should suppress any such regenerative response.
Another likely hypothesis is that global knock-out of JNK3 influ-
ences regeneration negatively through other KLF9-independent
downstream signaling events. Supporting this, previous studies
have shown that JNK phosphorylates JUN and DLK after optic
nerve crush (Huntwork-Rodriguez et al., 2013), both of which
are known to exert a proregenerative role (Ruff et al., 2012;
Tedeschi and Bradke, 2013; Watkins et al., 2013). Therefore, dis-
rupting the KLF9–JNK3 interaction lessens axon growth sup-
pression and promotes axon regeneration, whereas knocking out
JNK3 may lessen both growth suppression and growth promo-
tion pathways and result in a net nonregeneration phenotype, as
seen in our data. Additional exploration of JNK3 and KLF9 pro-
tein and gene targets will be an interesting direction for future
work.
Together, our data may suggest that injured RGCs initiate
stimulus-dependent pathways, triggering upstream kinases such
as DLK, which then respond by activating JNK family kinases.
These kinases not only mediate an orderly cell death program,
but also play a role in regulating regenerative neurite growth
capacity (both pro-growth and anti-growth) depending on the
particular balance of JNK isoforms involved, their localization,
and the particular cellular context. This would explain why KLF9
is amore potent neurite growth suppressor after it has been phos-
phorylated by JNK3, which itself is activated by upstream kinases
as well as cellular stress. Indeed, KLF9 expression itself has also
been shown to be induced directly by stressors through a
glucocorticoid-dependent mechanism in Xenopus brain (Bonett
et al., 2009). Whether JNK3 regulates KLFs in their diverse roles
outside of the CNS will be an important area for future study.
Finally, in characterizing the importance of KLF9’s JNK3-
binding domain and of two novel phosphorylation sites, S106
and S110, in KLF9’s suppressive activity on axon growth, these
data suggest that it is possible to interfere with the axon-sup-
pressive effects of KLF9 through dominant-negative constructs.
The effects of KLF9 knock-down are stronger than JNK3 inter-
ference, as expected, and may be explained by a larger pool of
endogenous KLF9 protein than can be readily inhibited by block-
ing the KLF9–JNK3 interaction. It may also be due to other rea-
sons, such as degradation of the short inhibiting peptide,
compensation from JNK2, or other modes of regulation of KLF9
activity, all of which could be quite interesting to address in fu-
ture study. Furthermore, all four BTEB subfamily KLFs (KLF9,
KLF13, KLF14, and KLF16) suppress axon growth in CNS neu-
rons (Moore et al., 2009) and contain a similar JNK3-binding
domain, indicating a structure–function relationship for these
KLFs in neurons. Although, in our preliminary experiments,
KLF13 was not able to pull down JNK3 fromwhole retinal lysates
(data not shown), it remains possible that the relatively low ex-
pression ofKLF13 comparedwithKLF9made it difficult to detect
an interaction. Future experiments could explore this hypothesis
more thoroughly by creating epitope-tagged versions of multiple
KLF family members, overexpressing them with epitope-tagged
JNK3, and conducting IP experiments from both sides using re-
spective antibodies in purified RGCs. Manipulations such as
these involving the expression of interfering peptides that disrupt
multiple KLF interactions with regulatory partners could prove
to be a useful strategy to promote axon regeneration and contrib-
ute to therapeutic approaches for addressing CNS injury and
degenerative disease.
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